Upper GI 2016

Meta-analyses

ü Preoperative Chemoradiation à Planned Esophagectomy

SVV Benefit for TMT

Author

Trials Period

pts

Notes

Urschel 2003 [Am J Surg] Fiorica 2004 [GUT] Arnott 2005 [IJROBP] Greer 2005 [Surgery] Gebski 2007* [Lancet Oncol] Jin 2009 [World J Gastr] Sjoquist 2011* [Lancet Oncol]

1992- 2002 1992- 2001 1981- 1992 1992- 2001 1982- 2006 1992- 2008 1983- 2004 1992- 2009

3 yy SVV benefit higher for concomitant vs sequential RTCT

9

1116

1-2-3 yy SVV

6

764

3 yy SVV

é postoperative mortality

Non significant trend at 2 and 5 yy Small non significant trend

5

1147

SCC 86%

6

738

Same trial selection Fiorica

10 (18)

1209 (2933 Tot)

2 yy SVV

Smaller significant benefit also for NACT

1-3-5 yy SVV

11

1308

14 (24)

2048 (4188 Tot)

2 yy SVV

CROSS reported as Abstract

Wang 2012 [Dig Dis Sci]

- SVV benefit only for concomitant RTCT - SVV benefit only for SCC

12

1529

1-3-5 yy SVV

Significant: ê Postop ✚ ê Loc Recs ê M+ Rates

- - -

“postoperative efficacy”

Deng 2014 [Diagn Pathol]

2001- 2013

Potential bias CROSS Included

13

1930

Fan 2016 [Thoracic Cancer]

5 (RTCT vs CT)

- Svv benefit of RTCT vs CT

2007- 2011

- RTCT perioperative mortality and complication rates higher than CT

678